Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Diagnostic Laboratory Immunology

• Publication date

  2005-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/CDLI.12.8.959-969.2005PMID 16085914PMCID PMC1182182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

  2005cited by this paper
• Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology.

  2005cited by this paper
• Christianity and Democracy: The Global Picture

  2004cited by this paper
• Human papillomavirus vaccines and prevention of cervical cancer.

  2004cited by this paper
• The estimated direct medical cost of sexually transmitted diseases among American youth, 2000.

  2004cited by this paper
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

  2004cited by this paper
• Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States.

  2004cited by this paper
• Gender Differences in Sexual Biomarkers and Behaviors Associated With Human Papillomavirus-16, −18, and −33 Seroprevalence

  2004cited by this paper
• Epidemiologic classification of human papillomavirus types associated with cervical cancer.

  2003cited by this paper
• Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia.

  2003cited by this paper
• Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland.

  2003cited by this paper
• Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay

  2003influential reference
• A controlled trial of a human papillomavirus type 16 vaccine.

  2002cited by this paper
• Seroprevalence of human papillomavirus type 16 infection in the United States.

  2002cited by this paper
• The causal relation between human papillomavirus and cervical cancer.

  2002cited by this paper
• Optimization of a Human Papillomavirus-Specific Enzyme-Linked Immunosorbent Assay

  2002cited by this paper
• Immune evasion in human papillomavirus-associated cervical cancer

  2002cited by this paper
• Cancer burden in the year 2000. The global picture.

  2001cited by this paper
• Determinants of genital human papillomavirus detection in a US population.

  2001cited by this paper
• Management of anogenital warts (condylomata acuminata).

  2001cited by this paper
• Management of anogenital warts (condylomata acuminata).

  2001cited by this paper
• Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.

  2001cited by this paper
• Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial.

  2000cited by this paper
• Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.

  2000cited by this paper
• Assembly of Human Papillomavirus Type 16 Pseudovirions in Saccharomyces cerevisiae

  2000cited by this paper
• Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group.

  2000cited by this paper
• Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae.

  1999cited by this paper
• Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women.

  1997cited by this paper
• A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera.

  1997cited by this paper
• Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae.

  1996cited by this paper
• Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae.

  1996cited by this paper
• Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.

  1996cited by this paper
• Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.

  1996cited by this paper
• Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae.

  1995cited by this paper
• Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective

  1995cited by this paper
• Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

  1995cited by this paper
• Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.

  1994cited by this paper
• Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11

  1990cited by this paper
• Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions.

  1986cited by this paper
• The use of phycobiliproteins as fluorescent labels in immunoassay.

  1986cited by this paper

• Comparative assessment of a multiplex micro-chip immunoassay, VaxArray, and meso scale discovery assay for serotype-specific coronavirus IgG quantitation.

  2025cites this paper
• Assessment of the ability of HPV vaccines to induce neutralizing antibodies based on pseudovirus-based neutralization assay

  2025cites this paper
• Beta Human Papillomaviruses Seropositivity and the Association With Cutaneous Squamous Cell Carcinoma—A Systematic Review and Meta‐Analysis

  2025cites this paper
• Clearance of anal and penile HPV 6, 11, 16, and 18 DNA and antibodies among adolescent men who have sex with men (HYPER): An observational cohort study

  2024cites this paper
• Prevalence and Risk Factors for HPV Seropositivity and Anogenital DNA-Positivity among Men Who Have Sex With Men: A Repeated Cross-Sectional Study.

  2024cites this paper
• RDE Treatment Prevents Non-Specific Detection of SARS-CoV-2- and Influenza-Specific IgG Antibodies in Heat-Inactivated Serum Samples

  2023cites this paper
• Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types

  2023cites this paper
• HEALTH EDUCATION OF THE POPULATION ABOUT THE PREVENTION POSSIBILITIES OF HPV INFECTION

  2023cites this paper
• Validation of Luminex immunological and competitive Luminex immunological assays for clinical immunogenicity assessment of a 14‐valent recombinant human papillomavirus vaccine

  2023cites this paper
• Development and application of HPV31-specific monoclonal antibodies

  2023cites this paper
• A case study and proposal for publishing directed acyclic graphs: The effectiveness of the quadrivalent human papillomavirus vaccine in perinatally HIV Infected girls.

  2022cites this paper
• Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies

  2022cites this paper
• Development and characterization of anti‐HPV16 monoclonal antibodies for assembly of an HPV16 detection kit

  2022cites this paper
• Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies

  2022cites this paper
• Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

  2022cites this paper
• Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women

  2022cites this paper
• Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants

  2022cites this paper
• Development of HPV58 type-specific antibodies and detection kit

  2022cites this paper
• Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11, 16 and 18.

  2021cites this paper
• Human papillomavirus antibody levels following vaccination or natural infection among young men who have sex with men.

  2021cites this paper
• Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial

  2021cites this paper
• Cytomegalovirus (CMV) Infection Suppresses The Expression Levels of Serum Cytokines in Follicular Lymphoma Patients

  2021cites this paper
• Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.

  2021cites this paper
• Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.

  2021cites this paper
• Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries

  2020cites this paper
• Background and Design of the Community Awareness Resources and Education (CARE) Project: Reducing Cervical Cancer in Appalachia

  2020cites this paper
• Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV.

  2020cites this paper
• Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes

  2020cites this paper
• Impact of heat-inactivation on the detection of SARS-CoV-2 IgM and IgG antibody by ELISA

  2020cites this paper
• Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study protocol: a randomised controlled trial of the efficacy of HPV vaccination in preventing transmission of HPV infection in heterosexual couples

  2020cites this paper
• In RRP, serologic response to HPV is frequently absent and slow to develop

  2020cites this paper
• Trypanosoma cruzi virulence factors for the diagnosis of Chagas´disease.

  2019cites this paper
• Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial

  2019cites this paper
• Establishment of xMAP for the simultaneous detection of antibodies to Newcastle disease virus and avian influenza virus

  2019cites this paper
• Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.

  2019cites this paper
• The genesis and evolution of bead-based multiplexing.

  2019cites this paper
• Is there evidence for efficacy of human papillomavirus vaccination in solid organ transplant recipients?

  2019cites this paper
• Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal.

  2019cites this paper
• Laryngeal Papilloma in Clinical Practice: Human Papillomavirus Infection and Vaccine Treatment

  2019cites this paper
• Human Papillomavirus Antibody Levels and Quadrivalent Vaccine Clinical Effectiveness in Perinatally Human Immunodeficiency Virus-infected and Exposed, Uninfected Youth.

  2019cites this paper
• Development and validation of a robust multiplex serological assay to quantify antibodies specific to pertussis antigens.

  2019cites this paper
• Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine When Co-Administered with Tetanus-Reduced Diphtheria-Acellular Pertussis and Quadrivalent Meningococcal Conjugate Vaccines in Healthy Adolescents: Results from a Randomized, Observer-Blind, Controlled Trial

  2019cites this paper
• Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.

  2019cites this paper
• Seroprevalence of human papillomavirus 6/11/16/18 among self-identified gay/bisexual men who have sex with men, men who have sex with women, and females, United States, 2003-2010.

  2018cites this paper
• Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development

  2018cites this paper
• A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298

  2018cites this paper
• The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules.

  2018cites this paper
• Development of a sensitive and specific xMAP assay for detection of antibodies against infectious laryngotracheitis and bronchitis viruses

  2018cites this paper
• Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing

  2018cites this paper
• Development and evaluation of two multi-antigen serological assays for the diagnosis of bovine tuberculosis in cattle.

  2018cites this paper
• L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine

  2018cites this paper
• Generalized ROC methods for immunogenicity data analysis of vaccine phase I studies in a seropositive population

  2018cites this paper
• 2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 - LBA/cell-based assays: immunogenicity, biomarkers and PK assays).

  2018cites this paper
• Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies

  2018cites this paper
• Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.

  2018cites this paper
• Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.

  2018cites this paper
• A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men

  2018cites this paper
• Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.

  2017cites this paper
• Decreased HHV-6 IgG in Alzheimer’s Disease

  2017cites this paper
• Top-down fabrication meets bottom-up synthesis for nanoelectronic barcoding of microparticles.

  2017cites this paper
• xMAP Technology: Applications in Detection of Pathogens

  2017cites this paper
• Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali

  2017cites this paper
• Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine

  2017cites this paper
• Gardasil Vaccination for Recurrent Laryngeal Papillomatosis in Adult Men: First Report: Changes in HPV Antibody Titer.

  2017cites this paper
• The effect of perceived psychological stress on the immunogenicity of the quadrivalent human papillomavirus vaccine in males

  2017cites this paper
• ImmunogenicityandReactogenicityofAlternative Schedules of HPV Vaccine in Vietnam

  2017cites this paper
• Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance

  2017cites this paper
• Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay

  2017cites this paper
• Impact of heat-inactivation on anti-Toxoplasma IgM antibody levels

  2017cites this paper
• 9-Valent human papillomavirus vaccine: a review of the clinical development program

  2017cites this paper
• Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females.

  2017cites this paper
• The Effect of Cytomegalovirus infection on Follicular Lymphoma biology

  2017cites this paper
• Functional assessment and structural basis of antibody binding to human papillomavirus capsid

  2016cites this paper
• Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.

  2016cites this paper
• HPV Vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee

  2016cites this paper
• Antibody responses following incident anal and penile infection with human papillomavirus in teenage men who have sex with men

  2016cites this paper
• Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women

  2016cites this paper
• Multiplexed molecular assays using nanoelectronically barcoded beads

  2016cites this paper
• Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD

  2016cites this paper
• Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD.

  2016cites this paper
• ORAL ABSTRACTS Viral Diseases and Vaccines

  2016cites this paper
• Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes

  2016cites this paper
• The Role of Multiplexed Assays in Vaccine Development

  2016cites this paper
• Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine

  2016cites this paper
• A Serological Epidemiological Survey of Antibodies against 4 HPV Subtypes in Uygur Women in Xinjiang.

  2016cites this paper
• Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.

  2016cites this paper
• The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies

  2016cites this paper
• Validation of a Microsphere Immunoassay for Serological Leptospirosis Diagnosis in Human Serum by Comparison to the Current Gold Standard

  2015cites this paper
• Using proportion of similar response to evaluate correlates of protection for vaccine efficacy

  2015cites this paper
• Seroprevalence and Seroincidence of Herpes Simplex Virus (2006–2010), Syphilis (2006–2010), and Vaccine-Preventable Human Papillomavirus Subtypes (2000–2010) Among US Military Personnel

  2015cites this paper
• Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine

  2015cites this paper
• Evaluation and Validation of the Detection of soluble Triggering Receptor Expressed on Myeloid Cells 1 by Enzyme-linked immunosorbent Assay

  2015cites this paper
• Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

  2015cites this paper
• Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types.

  2015cites this paper
• 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV

  2015cites this paper
• HPV Prevalence in Multiple Anatomical Sites among Men Who Have Sex with Men in Peru

  2015cites this paper
• Herpesvirus Infection and Immunity in Neurocognitive Disorders

  2015cites this paper
• The epidemiology of human papillomavirus in HIV-negative and HIV-infected men who have sex with men

  2015cites this paper
• Do vitamin D levels affect antibody titers produced in response to HPV vaccine?

  2015cites this paper
• Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected Women.

  2015cites this paper